Abstract
This major strategic analysis provides a detailed insight into the current and
future market for nano-enabled drug delivery technology.
Providing...
Critical analyses and competitive ratings for major specialist developers
Unique sales forecasts to 2015 for key current and new products utilising
nano-enabled drug delivery technologies A comprehensive examination of this
major drug delivery sector
Nanotechnology, the application of functional materials, devices, and systems
of matter in the sub-100 nanometre scale has the potential to improve the
delivery of approved and novel drugs through the design of nano-engineered
drugs and the development of a plethora of nano-carriers. Whilst the
pharmaceutical industry has been slow to invest resources into this innovative
technology, a number of nanotechnology-focused companies have become
established and are driving the future of this rapidly evolving market.
Companies are adopting different strategies to improve the therapeutic
potential, bioavailability, solubility and dosage of drugs through physical
manipulation of therapeutic agents e.g. nanocrystals, nanoparticles and
nanosuspensions as well as the targeted delivery of small molecule and large
molecular drugs using a range of nano-carriers e.g. carbon/ceramic
nanostructures, dendrimers, liposomes, micelles and polymer nanoparticles
Twelve nano-enabled products are now approved for the treatment of a range of
conditions from antibacterial infections to cancer and from the central
nervous system to metabolic disorders. These products utilise a range of
nanotechnologies including liposomes and polymeric micelles and have been
developed by a handful of companies. Together these products generated global
sales of over US$2.3 billion in 2006 and are forecast to reach sales of over
US$3 billion by 2009.
Competitive environment
The report identifies 22 companies which are evaluating nano-enabled products
in pre-clinical or clinical development. Of these, seven companies are likely
to have products that will reach the market by 2015.
A US$3.4 billion market in the making
By 2015, we forecast that nano-enabled products could generate sales in excess
of US$3.4 billion driven by the uptake of innovative drug delivery systems
including nanoparticle formulations, dendrimers and micelles and a new era of
biocompatible nanoparticle coatings will begin to emerge that have
applications in medical devices and dental implants. This is still very much
an emerging market and we believe considerable commercial opportunities still
exist for the pharma industry to form strategic alliances with
nano-specialists and to tap into this powerful technology that may help to
address the need for safer, more effective medicines.
View Cart
